Esplenomegalia gigante, dato indirecto de linfoma B de alto grado

María Virginia Herrero-García; Laura Rivero-Amador; Ana María Espejo-Gil; Araceli Rocío Romero-Dorado; Yapci Ramos-de León; Covadonga Rodríguez-Mangas

doi:10.32818/reccmi.a3n3a13

Giant splenomegaly, indirect evidence of high-grade B-cell lymphoma

Authors

María Virginia Herrero-García Servicio de Medicina Interna, Hospital Doctor José Molina Orosa, Arrecife (Las Palmas), Spain
Laura Rivero-Amador Servicio de Medicina Interna Familiar y Comunitaria, Hospital Doctor José Molina Orosa, Arrecife (Las Palmas), Spain
Ana María Espejo-Gil Servicio de Medicina Interna, Hospital Doctor José Molina Orosa, Arrecife (Las Palmas), Spain
Araceli Rocío Romero-Dorado Servicio de Cirugía General y Digestivo, Hospital Doctor José Molina Orosa, Arrecife (Las Palmas), Spain
Yapci Ramos-de León Servicio de Hematología, Hospital Doctor José Molina Orosa, Arrecife (Las Palmas), Spain
Covadonga Rodríguez-Mangas Servicio de Medicina Interna, Hospital Doctor José Molina Orosa, Arrecife (Las Palmas), Spain

DOI:

https://doi.org/10.32818/reccmi.a3n3a13

Keywords:

splenomegaly, splenectomy, high grade B-cell lymphoma, unclassifiable B-cell lymphoma

Abstract

A 44-year-old man presented with acute abdominal pain and splenomegaly. Splenectomy was performed by laparoscopy. We diagnosed as a high-grade B-cell lymphoma that is unclassifiable, with intermediate characte- ristics between diffuse large B-cell lymphoma and Hodgkin lymphoma based on its immunohistopathological examination.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Pozo AL, Godfrey EM, Bowles KM. Splenomegaly: investigation, diagnosis and management. Blood Rev. 2009; 23: 105-111.

Rodeghiero F, Ruggeri M. Short-and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications? Br J Haematol. 2012; 158: 16.

Renzulli P, Hostettler A, Schoepfer AM, et al. Systematic review of atraumatic splenic rupture. Br J Surg. 2009; 96: 1114.

Sehn LH. Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2012; 2012: 402-409.

Barton S, Hawkes EA, Wotherspoon A, Cunningham D. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks? Oncologist. 2012; 17(12): 1562-1573.

Shi F, Zhou Q, Gao Y, Cui X-Q, Chang H. Primary splenic B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a case report. Oncology letters 12. 2016; 1925-1928.

Szumera-Ciećkiewicz A, Rymkiewicz G, Gryga Lewicz B, Jesionek-Kupnicka D, Gruchała A, Ziarkiewicz-Wróblewska B, et al. Comprehensive histopathological diagnostics of aggressive B-cell lymphomas based on the updated criteria of the World Health Organisation’s 2017 classification. Pol J Pathol. 2018; 69(1): 1-19.

Bairey O, Shvidel L, Perry C, Dann EJ, Ruchlemer R, Tadmor T, Goldschamidt N. Primary Splenic Diffuse Large B-Cell Lymphoma (PS-DLBCL): splenectomy improves survival. Blood. 2014; 124: 4439.

Downloads

PDF (Español (España))

Published

2018-12-31

How to Cite

Herrero-García MV, Rivero-Amador L, Espejo-Gil AM, Romero-Dorado AR, Ramos-de León Y, Rodríguez-Mangas C. Giant splenomegaly, indirect evidence of high-grade B-cell lymphoma. Rev Esp Casos Clin Med Intern [Internet]. 2018 Dec. 31 [cited 2024 Nov. 21];3(3):140-3. Available from: https://www.reccmi.com/RECCMI/article/view/314

Download Citation

Issue

Vol. 3 No. 3 (2018): Spanish Journal of Case Records in Internal Medicine

Section

CLINICAL CASES

License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:

Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.

No comercial: no puede utilizar el material con fines comerciales.

No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.

Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.